Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: a pooled analysis of two randomized, controlled clinical trials.

@article{Major2001ZoledronicAI,
  title={Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: a pooled analysis of two randomized, controlled clinical trials.},
  author={Pierre P. Major and Alain Lortholary and Jeremy K Hon and Ehtesham A Abdi and Gordon Mills and Hans Dietrich Menssen and Furhan Yunus and Richard Bell and J J Body and Erhard Quebe-Fehling and John Seaman},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2001},
  volume={19 2},
  pages={558-67}
}
PURPOSE Two identical, concurrent, parallel, multicenter, randomized, double-blind, double-dummy trials were conducted to compare the efficacy and safety of zoledronic acid and pamidronate for treating hypercalcemia of malignancy (HCM). PATIENTS AND METHODS Patients with moderate to severe HCM (corrected serum calcium [CSC] > or = 3.00 mmol/L [12.0 mg/dL]) were treated with a single dose of zoledronic acid (4 or 8 mg) via 5-minute infusion or pamidronate (90 mg) via 2-hour infusion. A… CONTINUE READING
Highly Influential
This paper has highly influenced 11 other papers. REVIEW HIGHLY INFLUENTIAL CITATIONS
Recent Discussions
This paper has been referenced on Twitter 6 times over the past 90 days. VIEW TWEETS